Table 3 predictive factors by logistic regression analysis
From: Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis
variables | effective | non effective | odds ratio(95% CI) (monovariate) | P value | odds ratio(95% CI) (multivariate) | P value |
|---|---|---|---|---|---|---|
n = 19 | n = 8 |  |  |  |  | |
gender (male), n (%) | 7 (37) | 1 (13) | 4.1 (0.4–40) | 0.23 | 5.6 (0.28–115) | 0.26 |
age (≥ 65 year-old), n(%) | 6 (32) | 2 (25) | 1.4 (0.2–9.0) | 0.73 | 1.2 (0.05–26.6) | 0.92 |
duration of asthma (≥ 20 years), n(%) | 11 (58) | 4 (50) | 1.4 (0.3–7.2) | 0.71 | – | – |
BMI(kg/m2) ≥ 25, n (%) | 6 (32) | 2 (25) | 1.4 (0.2–9.0) | 0.73 | – | – |
atopic type, n(%) | 16 (84) | 5 (63) | 3.2 (0.5–21) | 0.23 | – | – |
blood eosinophil count≥150(/mm3)a, n (%) | 18 (95) | 7 (88) | 2.6 (0.1–47) | 0.54 | – | – |
FeNO≥50(ppb)a, n (%) | 9 (47) | 3 (38) | 1.5 (0.3–8.1) | 0.64 | – | – |
with maintenance therapy of OCS, n (%) | 10 (59) | 7 (75) | 0.1 (0.01–1.3) | 0.078 | 0.05 (0.001–1.5) | 0.08 |
with ECRS as comorbidity, n (%) | 14 (74) | 2 (25) | 8.4 (1.3–56) | 0.028 | 22.5 (1.5–336) | 0.024 |